Literature DB >> 9779062

[The demonstration of blood flow in focal breast lesions by power-Doppler sonography. A new approach to assessment?].

P Milz1, M Kessler, A Lienemann, N Opitz, M Reiser.   

Abstract

PURPOSE: Power-Doppler sonography is regarded as a very sensitive method for detecting low-velocity and low-volume blood flows. The purpose of our study was to investigate whether increased vascularity in breast carcinoma can be visualized by power-Doppler sonography and whether new criteria for differentiating benign and malign lesions can be found.
METHOD: 315 patients were examined with a 13-MHz high-resolution linear transducer. If a suspicious lesion was found, it was evaluated further by power-Doppler sonography. Compared to normal breast parenchyma (reference structure), a focal increase in blood flow signals was registered using a 3-step grading system with a 4th step for no flow increase.
RESULTS: In 97 cases the sonographic findings were correlated with histology (n = 95) or cytology (n = 2). There were 50 benign lesions, 42 cases of invasive and 5 cases of in-situ carcinoma. 73.5% benign lesions showed no or just minimal increases in flow signal. 81% of invasive cancer presented middle- or high-flow increases compared to normal breast parenchyma. The extend of flow increase was linked to tumor size in invasive cancer. In stage T1b to T4, 94.3% of invasive carcinoma presented middle or high flow increases.
CONCLUSION: Power-Doppler sonography is able to visualize vascularization in breast tumors. According to first clinical results PD sonography is a promising additional diagnostic tool which seems to offer new criteria for differential diagnosis in breast tumors.

Entities:  

Mesh:

Year:  1998        PMID: 9779062     DOI: 10.1055/s-2007-1015084

Source DB:  PubMed          Journal:  Rofo        ISSN: 1438-9010


  1 in total

1.  [3D ultrasound (3D US) in the diagnosis of focal breast lesions].

Authors:  D Kotsianos; S Wirth; T Fischer; K Hiltawsky; H Sittek; M Reiser
Journal:  Radiologe       Date:  2005-03       Impact factor: 0.635

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.